Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,130 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04568564 | Telerehabilitation in Lung Surgery Patients | completed | N/A | 40 | Istanbul Medipol University HospitalOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06832592 | Supportive Care Needs of Bronchial Cancer Patients in Active Treatment: A Descriptive Study in Outpatient Oncology | completed | — | 100 | L'hôpital Nord-Ouest - Villefranche Villefranche sur SaôneOTHER | 1 | Apr 8, 2025 |
| clinicaltrials |
| NCT04364620 | AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) | completed | Phase 2 | 35 | Alethia BiotherapeuticsINDUSTRY | 2 | Apr 6, 2025 | clinicaltrials |
| NCT03197467 | Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer(NEOMUN) | completed | Phase 2 | 30 | AIO-Studien-gGmbHOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT04323618 | Investigation of Respiratory-related Tumour Motion in Liver Cancer Patients Undergoing SBRT Using Audiovisual Biofeedback(LAVA) | completed | N/A | 5 | University of SydneyOTHER | 0 | Apr 4, 2025 | clinicaltrials |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | completed | Phase 1 | 269 | ExelixisINDUSTRY | 9 | Apr 4, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT04507828 | Combined Deep Inspiration Breath Hold (DIBH)-Expiration Planning Technique in Patients With Lung Tumors in Close Proximity to the Chest Wall | completed | N/A | 4 | Indiana UniversityOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT04735068 | Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer | completed | Phase 2 | 9 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05834348 | A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.(DELINOR) | completed | — | 5,279 | PfizerINDUSTRY | 1 | Mar 30, 2025 | clinicaltrials |
| NCT05298176 | Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors(COMBINATION) | completed | Phase 2 | 5 | Amsterdam UMC, location VUmcOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT02922764 | A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer | completed | Phase 1 | 146 | Inspirna, Inc.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT03389399 | Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases | completed | — | 18 | University of Colorado, DenverOTHER | 2 | Mar 25, 2025 | clinicaltrials |
| NCT03631784 | A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)(KEYNOTE-799) | completed | Phase 2 | 216 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 25, 2025 | clinicaltrials |
| NCT02582125 | ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 53 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 24, 2025 | clinicaltrials |
| NCT03526887 | Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC(Replay) | completed | Phase 2 | 73 | Spanish Lung Cancer GroupOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT03195699 | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers | completed | Phase 1 | 64 | Tvardi Therapeutics, IncorporatedINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04003246 | Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 10 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05137067 | A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents. | completed | Phase 2 | 90 | Optimal Health ResearchOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05337163 | A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China | completed | — | 1,564 | Creative Biosciences (Guangzhou) Co., Ltd.INDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT02437136 | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) | completed | Phase 1 / Phase 2 | 191 | Syndax PharmaceuticalsINDUSTRY | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04256707 | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment(SPRINT) | completed | Phase 1 / Phase 2 | 126 | Karyopharm Therapeutics IncINDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02489903 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | completed | Phase 2 | 139 | EpicentRx, Inc.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT03676192 | To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 689 | CelltrionINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT05058560 | Tislelizumab in Addition to BACE in Patients with NSCLC | completed | Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04172506 | A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 65 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04934865 | Real Life Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG(REAL-MOOV-LUNG) | completed | N/A | 240 | Institut CurieOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05505825 | A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | AkesoINDUSTRY | 2 | Mar 12, 2025 | clinicaltrials |
| NCT06536140 | The Lived Experiences of Persons With Early Stage Non-small Cell Lung Cancer and Their Significant Other(s) Following Surgery: a Rapid Ethnographic Approach(LEILA) | completed | — | 16 | Hasselt UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04960735 | Implementation, Effectiveness and Impact of a Value Based Intervention for Patients with Breast or Lung Cancer(VOICE) | completed | N/A | 1,007 | Biosistemak Institute for Health Systems ResearchOTHER | 5 | Mar 10, 2025 | clinicaltrials |
| NCT05619744 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | completed | Phase 1 | 41 | Hoffmann-La RocheINDUSTRY | 5 | Mar 10, 2025 | clinicaltrials |
| NCT05697198 | PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine(PREFER) | completed | — | 1,429 | Labcorp Corporation of America Holdings, IncINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT00446225 | Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR(EURTAC) | completed | Phase 3 | 174 | Spanish Lung Cancer GroupOTHER | 3 | Mar 5, 2025 | clinicaltrials |
| NCT03868579 | Rapid On Site Evaluation of Pleural Touch Preparations in Diagnosing Malignant Pleural Effusion in Patients Undergoing Pleuroscopy | completed | N/A | 97 | M.D. Anderson Cancer CenterOTHER | 2 | Mar 5, 2025 | clinicaltrials |
| NCT06495008 | Taste and Smell Dysfunction in Patients More Than Two Years After Start of Immune Checkpoint Inhibitor Therapy(TasteSPICIER) | completed | — | 101 | University Medical Center GroningenOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT03812549 | Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients | completed | Phase 1 | 29 | Sichuan UniversityOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT06855966 | Feasibility of ETCO₂ Changes During Passive Leg Raise for Fluid Management in Lung Surgery | completed | N/A | 53 | Istanbul University - CerrahpasaOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT02535338 | Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04880863 | NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC(NT-NAP-102-1) | completed | Phase 2 | 38 | NeoTX Therapeutics Ltd.INDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04005716 | Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer | completed | Phase 3 | 457 | BeiGeneINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04182815 | Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors of the Lung(TARGET) | completed | — | 691 | Auris Health, Inc.INDUSTRY | 3 | Feb 28, 2025 | clinicaltrials |
| NCT04206787 | The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer | completed | — | 72 | Boehringer IngelheimINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6(IT-01) | completed | Phase 1 / Phase 2 | 111 | Intensity Therapeutics, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT03089125 | Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer | completed | N/A | 247 | Massachusetts General HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT03543683 | Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC | completed | Phase 2 | 115 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06168825 | Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive Intervention(MOM) | completed | — | 40 | Inova Health Care ServicesOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT02424617 | A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 40 | BerGenBio ASAINDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT05131815 | The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors | completed | N/A | 8 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04997382 | Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC(CLASSIC5) | completed | Phase 2 | 112 | Hunan Province Tumor HospitalOTHER | 1 | Feb 25, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Apr 8, 2025source: clinicaltrials